Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of immunoglobulin G4(IgG4) in allergic diseases is still worth exploring.we have collected the data of allergic patients aged 0-14 years for retrospective cross-sectional analysis to evaluate the positive rates of total IgE, HDM IgE, FS-IgE and FS-IgG4. Meanwhile, investigators screened out patients who were treated with FS-IgG4-guided elimination diets with/without probiotics for more than 3 months to clarify the role of FS-IgG4 in childhood allergic diseases by assessing the improvement of clinical symptoms before and after treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age of participants
Timeframe: 2018.1-2020.12
Gender ratio of participants
Timeframe: 2018.1-2020.12
birth mode of participants
Timeframe: 2018.1-2020.12
Family history of allergies of the participants
Timeframe: 2018.1-2020.12
total IgE
Timeframe: 2018.1-2020.12
FS-IgE
Timeframe: 2018.1-2020.12
HDM-IgE
Timeframe: 2018.1-2020.12
FS-IgG4
Timeframe: 2018.1-2020.12
The difference of total-IgE and FS-IgG4 positive rates among the three groups
Timeframe: 2018.1-2020.12
The difference of FS-IgE and FS-IgG4 positive rates among the three groups
Timeframe: 2018.1-2020.12
Comparison of FS-IgG4 positive rates among the three groups
Timeframe: 2018.1-2020.12